Cancer Research
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Excerpt from the Press Release: REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results…
4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to Therapy Excerpt from the Press Release: NEWTON, Mass., Jan. 22, 2026 (GLOBE NEWSWIRE) — 4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory biomarker collaborator in the…
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior systemic therapy including patients who are…
Company plans to initiate a Phase 1 clinical study by 1H2026 and share data in 2027 Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, announced that the U.S. Food and Drug Administration…
Company to present at J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study evaluating EPI-321, an investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD). Epicrispr holds the first and only…
Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology 10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests Excerpt from the Press Release: PLEASANTON, Calif., Jan.…
Company provides 2026 corporate outlook highlighting multiple clinical catalysts across first-in-class cardioendocrine pipeline MAR002 Phase 1 Data: Robust, durable IGF-1 suppression supports potential for biweekly to monthly dosing; Phase 2/3 study initiation expected mid-2026 MAR001 Phase 2b TYDAL-TIMI 78 Study Enrollment Nearing Completion: multiple data readouts expected throughout 2026; advancing half-life-extended MAR001-HLE designed for infrequent,…
— Study Results Support the use of TellDx to Personalize Cancer Care Management – — Clinical study published in Cancer Discovery — Excerpt from the Press Release: ANDOVER, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) — TellBio, Inc., a medical technology company focused on revolutionizing the management of cancer through its unique and proprietary circulating tumor…
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with cizutamig (BCMA TCE) and CND261 (CD20 TCE). Clinical evaluation is ongoing under multiple active INDs, investigator-initiated trials and compassionate use across…
– Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare – – Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints – – Obexelimab was well tolerated and no new safety signals were observed – – Zenas anticipates…